Amiodarone Treatment in Patients with Ventricular Arrhythmias

Eric N. Prystowsky, James J. Heger, William M. Miles, Douglas P. Zipes

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Amidarone has been used in the therapy of supraventricular and ventricular tachycardia, and has often been categorised as a class III rather than a class I agent. However, in patients with ventricular arrhythmias, amiodarone 800 mg daily for 14 days prolonged the right ventricular effective refractory period by a mean of 18.8 msec (p < 0.05), and HV interval by a mean of 5.2 msec (p < 0.05), these changes being similar to those noted with drugs such as quinidine, procainamide, disopyramide and encainide. The antiarrhythmic efficacy of amiodarone was evaluated in 196 patients with recurrent sustained ventricular tachycardia, recurrent ventricular fibrillation or recurrent nonsustained ventricular tachycardia. Coronary artery disease, dilated (congestive) cardiomyopathy, or other forms of heart disease were present in most patients. After 1 month of therapy, 177 patients continued to receive amiodarone and, during the remainder of the follow-up period, 139 patients had no recurrence of spontaneous ventricular tachycardia of ventricular fibrillation. Sudden cardiac death occurred in 15 patients after a mean treatment period of 10.4 months. Overall, amiodarone was an effective form of therapy in patients with ventricular tachycardia and ventricular fibrillation.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
Issue number3
StatePublished - Apr 1985

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Amiodarone Treatment in Patients with Ventricular Arrhythmias'. Together they form a unique fingerprint.

Cite this